ExCellThera annonce
ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
December 12, 2023 07:00 ET | ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...
ExCellThera Announce
ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting
December 12, 2023 07:00 ET | ExCellThera
50 patients evaluated in Phase 2 studies; ExCellThera’s UM171 showed excellent clinical outcomes for this high-risk leukemia/myelodysplasia cohort
ExCellThera_RGB.png
ExCellThera announces new UM171 data to be presented at ASH 2023
November 03, 2023 08:15 ET | ExCellThera
ExCellThera announced today several UM171 presentations at ASH2023, including new data from Phase 2 studies in high-risk blood cancer patients
biomerica.png
Biomerica Reports Fiscal 2023 Year End Results
August 25, 2023 17:00 ET | Biomerica, Inc.
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US ...
zealand_logo_RGB_01.png
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023 17:15 ET | Zealand Pharma
Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
biomerica.png
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
March 08, 2023 08:19 ET | Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...
biomerica.png
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
November 02, 2022 08:19 ET | Biomerica, Inc.
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific MeetingThe Presented Clinical Study Data Showed InFoods® IBS...
zealand_logo_RGB_01.png
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
September 21, 2022 08:15 ET | Zealand Pharma
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) ...
xequelbio_digital.jpg
Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
July 14, 2022 09:00 ET | Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
LMAO logo.jpg
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
June 07, 2022 08:30 ET | LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital...